CHD1L and adenocarcinoma: Using this criteria, CHD1L overexpression was observed in 98/233 (42.1%) of the NSCLCs, 58/109 (53.2%) of the adenocarcinomas (ADCs) and 25/89 (28.1%) of the squamous cell carcinomas (SCCs), respectively (Fig. 1).